MX2019007891A - Sales de oxalato de tianeptina y polimorfos. - Google Patents

Sales de oxalato de tianeptina y polimorfos.

Info

Publication number
MX2019007891A
MX2019007891A MX2019007891A MX2019007891A MX2019007891A MX 2019007891 A MX2019007891 A MX 2019007891A MX 2019007891 A MX2019007891 A MX 2019007891A MX 2019007891 A MX2019007891 A MX 2019007891A MX 2019007891 A MX2019007891 A MX 2019007891A
Authority
MX
Mexico
Prior art keywords
polymorphs
tianeptine
oxalate salts
tianeptine oxalate
oxalate
Prior art date
Application number
MX2019007891A
Other languages
English (en)
Inventor
Luca Giaffreda Stefano
Modena Enrico
Fabbroni Serena
Chiarucci Michel
T Edgar Mark
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Publication of MX2019007891A publication Critical patent/MX2019007891A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se da a conocer una sal o un co-cristal de oxalato (oxalato de tianeptina) de S,S-dióxido del ácido (RS)-7-(3-cloro-6-metil-6,11-dihidro-dibenzo-[c,f] [1,2]-tiazepin-11-il-amino)-heptanoico (tianeptina) como se muestra en la fórmula I: (Ver fórmula).
MX2019007891A 2016-12-28 2017-12-28 Sales de oxalato de tianeptina y polimorfos. MX2019007891A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662439533P 2016-12-28 2016-12-28
PCT/IB2017/001709 WO2018122606A1 (en) 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs

Publications (1)

Publication Number Publication Date
MX2019007891A true MX2019007891A (es) 2019-12-16

Family

ID=61283255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007891A MX2019007891A (es) 2016-12-28 2017-12-28 Sales de oxalato de tianeptina y polimorfos.

Country Status (12)

Country Link
US (2) US10449203B2 (es)
EP (1) EP3562812A1 (es)
JP (2) JP2020503330A (es)
CN (1) CN110418785A (es)
AU (1) AU2017385958B2 (es)
BR (1) BR112019013244A2 (es)
CA (1) CA3048324A1 (es)
IL (1) IL267708A (es)
MX (1) MX2019007891A (es)
NZ (1) NZ754797A (es)
WO (1) WO2018122606A1 (es)
ZA (1) ZA201904185B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019013244A2 (pt) * 2016-12-28 2019-12-24 Tonix Pharma Holdings Ltd sais e polimorfos de oxalato de tianeptina
WO2022197719A1 (en) 2021-03-15 2022-09-22 Tonix Pharmaceuticals Holding Corp. Tianeptine oxalate and naloxone combination for the treatment of major depressive disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635461B1 (fr) * 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
US5405842A (en) 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
FR2791891A1 (fr) 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
BR112019013244A2 (pt) * 2016-12-28 2019-12-24 Tonix Pharma Holdings Ltd sais e polimorfos de oxalato de tianeptina

Also Published As

Publication number Publication date
WO2018122606A1 (en) 2018-07-05
US20180338984A1 (en) 2018-11-29
NZ754797A (en) 2022-05-27
US10946027B2 (en) 2021-03-16
CA3048324A1 (en) 2018-07-05
AU2017385958B2 (en) 2021-12-02
IL267708A (en) 2019-08-29
BR112019013244A2 (pt) 2019-12-24
AU2017385958A1 (en) 2019-07-11
US10449203B2 (en) 2019-10-22
JP2020503330A (ja) 2020-01-30
CN110418785A (zh) 2019-11-05
ZA201904185B (en) 2021-10-27
JP2023001340A (ja) 2023-01-04
US20200276208A1 (en) 2020-09-03
EP3562812A1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
PH12017502171B1 (en) PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CL2017002179A1 (es) Sales de inhibidor de pi3k y procesos de preparación
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
EA201690911A1 (ru) Соединения диметилбензойной кислоты
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MX2015013745A (es) Preparacion de intermediarios de pirimidina utiles para la preparacion de maci tentano.
NZ712660A (en) Dicarboxylic acid compound
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
MX2019007891A (es) Sales de oxalato de tianeptina y polimorfos.
MX2016010564A (es) Procesos para preparar moduladores del canal ionico heterociclico fusionado.
AR092772A1 (es) Derivado de 7-azaindol
BR112017007027A2 (pt) melhorias nos compostos orgânicos ou relativas aos mesmos
BR112017004166A2 (pt) sal de derivado de cefalosporina, forma sólida cristalina do mesmo e método para produzir o mesmo
BR112015017919A8 (pt) preparação líquida aquosa e método para clarificar uma preparação líquida aquosa
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
CR20170261A (es) Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa
LV14895A (lv) 5-monoaizvietotu 2-mono- vai 2,2-diaizvietotu 1,3-dioksān-4,6-dionu savienojumi kā antiradikāļu aģenti un antioksidanti
MX2019004732A (es) Proceso para la preparacion de 4-isopropil-6, 7-dihidro-3h-imidazo[4,5-c] piridin-5(4h)-carboxilato de (3s, 4s)-tetrahidrofuran-3-ilo.